Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Elan Pharmaceuticals Inc
Elan Pharmaceuticals Inc_20100121
Elan Pharmaceuticals Inc_20100128
  

Elan Pharmaceuticals Inc patents

Recent patent applications related to Elan Pharmaceuticals Inc. Elan Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Elan Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Elan Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Elan Pharmaceuticals Inc-related inventors




Date Elan Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
10/08/15Inhibitors of lrrk2 kinase activity
05/07/15Inhibitors of polo-like kinase
08/28/14Methods of treating behavioral and psychiatric disorders
07/10/14Combination treatments for bipolar disorders
07/03/14Phagocytic activity as a marker of synucleinopathic disease
05/15/14Treatment and prophylaxis of amyloidosis
03/13/14Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
02/20/14Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
12/19/13Multimeric vla-4 antagonists comprising polymers moieties
11/28/13Antibodies to alpha-synuclein
09/26/13Pyridinone antagonists of alpha-4 integrins
09/05/13Inhibitors of polo-like kinase
03/21/13Inhibitors of jun n-terminal kinase
03/21/13Antibodies to alpha synuclein
03/07/13Therapeutic uses of humanized antibodies against alpha-4 integrin
01/17/13Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
12/27/12Immunoglobulin formulation and preparation thereof
12/27/12Multimeric vla-4 antagonists comprising polymers moieties
12/20/12Treatment and prophylaxis of amyloidosis
10/25/12N-substituted benzene sulfonamides
08/09/12Prevention and treatment of synucleinopathic and amyloidogenic disease
08/02/12Methods and products for evaluating an immune response to a therapeutic protein
07/26/12Treatment and prophylaxis of amyloidosis
07/12/12Methods of treating inflammatory and autoimmune diseases with natalizumab
06/07/12Prevention and treatment of synucleinopathic and amyloidogenic disease
05/10/12Inhibitors of polo-like kinase
03/08/12Selective integrin inhibitors
02/16/12Treatment and prophylaxis of amyloidosis
12/15/11Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
12/01/11Alzheimer's disease secretase, app substrates therefor, and uses therefor
11/24/11Prevention and treatment of amyloidogenic diseases
11/17/11Beta-secretase enzyme compositions and methods
09/01/11Inhibitors of polo-like kinase
08/25/11Inhibitors of polo-like kinase
07/21/11Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
03/17/11Administration of agents for the treatment of inflammation
03/17/11Prevention and treatment of amyloidogenic disease
02/10/11Process for the production of fused, tricyclic sulfonamides
01/13/11Pyridinone antagonists of alpha-4 integrins
01/06/11Bridged n-cyclic sulfonamido inhibitors of gamma secretase
12/02/10Signaling intermediates in an in vitro model of alzheimer's disease
10/21/105-(arylsulfonyl)-pyrazolopiperidines
08/12/10Antibodies to alpha-synuclein
08/05/10Methods of treating inflammatory and autoimmune diseases with natalizumab
06/17/10Methods of treatment of hyperuricemia and associated disease states
05/06/10Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
04/22/10Processes and intermediates for preparing benzyle epoxides
04/08/10Prevention and treatment of synucleinopathic and amyloidogenic disease
04/01/10Therapeutic uses of humanized antibodies against alpha-4 integrin
02/04/10Prevention and treatment of synucleinopathic and amyloidogenic disease
01/28/10Immunoglobulin formulation and preparation thereof
01/21/10Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
12/17/09Methods and compositions for treating liquid tumors
11/26/09Substituted aminoethers for the treatment of alzheimer's disease
11/19/09Prevention and treatment of amyloidogenic diseases
11/19/09Prevention and treatment of amyloidogenic disease
11/19/09Glycosylation variants of bace
10/29/09Substituted hydroxyethylamine aspartyl protease inhibitors
09/10/09Thermal denaturation screening assay to identify candidate compounds for prevention and treatment of parkinson's disease
09/10/09Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
09/10/09Methods for using modulators of proline-rich tyrosine kinase 2
08/20/09Prevention and treatment of synucleinopathic and amyloidogenic disease
08/20/09Lyophilized immunoglobulin formulations and methods of preparation
08/13/09Treatment and prophylaxis of amyloidosis
07/02/09Crystallization and structure determination of bace and/or bace-like proteins
Patent Packs
06/25/09Triple assay system for identifying substrate selectivity of gamma secretase inhibitors
06/04/09Beta-secretase enzyme compositions and methods
02/05/09Truncated fragments of alpha-synuclein in lewy body disease
01/28/10Immunoglobulin formulation and preparation thereof
01/21/10Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Elan Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';